Impact of postharvest processing on the health benefits of durian-derived products.

Durian (Durio zibethinus Murr.) is a seasonal fruit with a short harvesting period, requiring postharvest processing such as cutting, peeling, freeze-drying, cooking, and frying to enhance its shelf life and nutritional quality. In this study, fresh Monthong durian (MTD), MTD Sticks, MTD Cake, and MTD Chips were analyzed for polyphenols, phenolic acids, tannins, flavonoids and thermal stability.

Targeted CRISPR/Cas9 Lipid Nanoparticles Elicits Therapeutic Genome Editing in Head and Neck Cancer.

Squamous cell carcinomas of the head and neck (HNSCC) originate in the upper aerodigestive tract, including the oral cavity, pharynx, and larynx. Current treatments of locally advanced HNSCC often lead to high treatment failure, and disease recurrence, resulting in poor survival rates. Advances in mRNA technologies and lipid nanoparticle (LNP) delivery systems led to several clinical trials involving LNP-CRISPR-Cas9 mRNA-based therapeutics.

Lipid Nanoparticles With Fine-Tuned Composition Show Enhanced Colon Targeting as a Platform for mRNA Therapeutics.

Lipid Nanoparticles (LNPs) recently emerged as an invaluable RNA delivery platform. With many LNP-based therapeutics in the pre-clinical and clinical pipelines, there is extensive research dedicated to improving LNPs. These efforts focus mainly on the tolerability and transfectability of new ionizable lipids and RNAs, or modulating LNPs biodistribution with active targeting strategies.

Discriminating Parkinson's disease patients from healthy controls using nasal respiratory airflow.

Background: Breathing patterns may inform on health. We note that the sites of earliest brain damage in Parkinson's disease (PD) house the neural pace-makers of respiration. We therefore hypothesized that ongoing long-term temporal dynamics of respiration may be altered in PD.

Levodopa-carbidopa intestinal gel for advanced Parkinson's disease: Impact of LRRK2 and GBA1 mutations.

Background: Advanced Parkinson's disease (PD) can be treated with Levodopa-Carbidopa Intestinal Gel (LCIG).

Objective: To compare descriptive data of LCIG treatment in GBA1-PD and LRRK2-PD.

Methods: This multicenter retrospective study compared clinical data obtained from electronic medical records of PD patients treated with LCIG.